Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 53, 2018 - Issue 10-11
Submit an article Journal homepage
3,042
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

Sara RundquistDepartment of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; ORCID Iconhttp://orcid.org/0000-0002-4923-3169
ORCID Icon,
Carl ErikssonDepartment of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; ORCID Iconhttp://orcid.org/0000-0002-1046-383X
ORCID Icon,
Linda NilssonDepartment of Internal Medicine, Danderyd Hospital, Stockholm, Sweden;
,
Leif AngelisonDepartment of Internal Medicine, Helsingborg Hospital, Helsingborg, Sweden;
,
Susanna JäghultStockholm Gastro Center, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden;
,
Jan BjörkDepartment of Medicine, Center for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden;
,
Olof GripDepartment of Gastroenterology, Skåne University Hospital Malmö, Malmö, Sweden;
,
Henrik HjortswangDepartment of Gastroenterology, Linköping University, Linköping, Sweden;
,
Hans StridDepartment of Internal Medicine, Södra Älvsborgs Sjukhus, Borås, Sweden;
,
Per KarlénDepartment of Internal Medicine, Danderyd Hospital, Stockholm, Sweden;
,
Scott MontgomeryClinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden; ;Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; ;Department of Epidemiology and Public Health, University College London, London, UK
&
Jonas HalfvarsonDepartment of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Correspondence[email protected]
 show all
Pages 1257-1263 | Received 11 Jul 2018, Accepted 28 Aug 2018, Published online: 24 Oct 2018

References

  • Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078.
  • Gomollon F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohn's Colitis. 2017;11:3–25.
  • Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohn's Colitis. 2013;7:827–851.
  • Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375:1946–1960.
  • Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohn's Colitis. 2010;4:355–366.
  • Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24–30.
  • Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. Ann Intern Med. 2007;146:829–838.
  • Rutgeerts P, Feagan BG, Marano CW, et al. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015;42:504–514.
  • Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85–95.
  • Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96–109.e1.
  • Merras-Salmio L, Kolho KL. Golimumab therapy in six patients with severe pediatric onset Crohn disease. J Pediatr Gastroenterol Nutr. 2016;63:344–347.
  • Ben-Bassat O, Iacono A, Irwin SP, et al. Tu1327a golimumab for treatment of moderate to severe anti-TNF refaractory Crohn's disease: open label experience. Gastroenterology. 2012;142:S-804.
  • Martineau C, Flourie B, Wils P, et al. Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. Aliment Pharmacol Ther. 2017;46(11–12):1077–1084.
  • Greener T, Boland K, Steinhart AH, et al. The unfinished symphony: golimumab therapy for anti-TNF refractory Crohn's disease. J Crohn's Colitis. 2018;12(4):458–464.
  • Busch K, Ludvigsson JF, Ekstrom-Smedby K, et al. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39:57–68.
  • SWIBREG: Swedish Inflammatory Bowel Disease Registry [cited 2018 April 13]. Available from: http://www.swibreg.se/
  • Ludvigsson JF, Myrelid P. [Swibreg–a new version of national IBD registry]. Lakartidningen. 2009;106:3014–3015. Swedish.
  • Jakobsson GL, Sternegard E, Olen O, et al. Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG). Scand J Gastroenterol. 2017;52:216–221.
  • Hornung RW, Reed LD. Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg. 1990;5:46–51.
  • Gordon JP, McEwan PC, Maguire A, et al. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol. 2015;27:804–812.
  • Lopetuso LR, Gerardi V, Papa V, et al. Can we predict the efficacy of anti-TNF-alpha agents? Ijms. 2017;18:1973.
  • Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther. 2016;43:30–51.
  • Narula N, Kainz S, Petritsch W, et al. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-alpha naive Crohn's disease. Aliment Pharmacol Ther. 2016;44:170–180.
  • Cosnes J, Sokol H, Bourrier A, et al. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. Aliment Pharmacol Ther. 2016;44:1102–1113.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.